Cardiovascular Disease

Cardiovascular disease continues to be an ever-growing global health issue and remains the leading cause of death worldwide. While it is a preventable disease, developing new methods and technologies to investigate and fight this disease remains a top priority.

Cardiovascular Disease

Regardless of what stage your research is in, Charles River’s comprehensive portfolio of products and services provides you with the necessary resources to advance your cardiovascular studies. With an array of disease models, surgical procedures, preclinical cardiac risk assessment services, tailored specialty toxicology services, and much more, we anticipate challenges and are an expert partner to move your studies to their next phase. 

Charles River provides animal models specific for cardiovascular disease research. And, if your research requires the use of specialized or genetically modified models, our experts can work with you to customize and create them for your study using the latest model creation technologies. Through our preconditioning services, we offer an array of cardiovascular surgical procedures and custom diets so that you receive your animal study ready.

Basic Research Products & Services

While considerable progress has been made in recent years, cardiovascular disease continues to be a leading cause of death globally, and the number of people exhibiting risk factors for developing cardiovascular disease has been increasing. For these reasons, cardiovascular disease drug discovery remains a critical area of focus within the scientific community. Whether targeting cardiovascular diseases like coronary artery disease or hypertension directly, or any of the disorders that increase cardiovascular disease risk (collectively known as metabolic syndrome), Charles River helps accelerate your discoveries through innovative target identification and validation, complex in vitro and in vivo pharmacology models, and a strong chemistry and disease biology foundation, all of which assist in translating basic research to clinical reality.


Our teams combine sophisticated genetic manipulation techniques with complex cell-based assays, including those developed in stem cells, primary human or rodent cells, and patient-derived cells, to identify and validate novel targets, or provide disease-relevant in vitro models for early efficacy, target engagement, and toxicology assessment.


Effective small molecule drug discovery requires a strong partnership between the biologists and chemists working on the program. A thorough understanding of the biology of the target is critical to generating and optimizing compounds with the most favorable characteristics for efficacy and safety, while a thorough understanding of chemistry is required to insure novel, selective, and high-quality development candidates. Working together, chemists and biologists at Charles River have produced over 75 development candidates since 2001 and been named as inventors on over 320 patents for our partners over the same period of time.


It is critical to select the appropriate in vivo pharmacology models for the assessment of candidates designed to treat obesity, diabetes, fatty liver disease, atherosclerosis, vascular inflammation, and other cardiovascular diseases. Our scientists will work with you to select not only the appropriate animal models, but also recommend the most appropriate translational biomarkers to demonstrate in vivo target engagement and therapeutic efficacy of your articles.

Cardiovascular Resources

Establishing a thorough understanding of your compound’s safety and efficacy profile is crucial for mitigating potential risks and advancing your program. Access to an integrated scientific network, spanning drug discovery and preclinical development, can provide insight into potential risks earlier from both a regulatory and safety perspective.

Charles River’s integrated in-vitro and in-vivo cardiovascular experts provide a comprehensive approach and the expert interpretations needed to understand the pathophysiological foundation of cardiovascular disorders and facilitate translational efforts to help you find new cardiovascular therapies and advance your program. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and aid a smooth transition to the clinic.

Safety Assessment Services

We offer full-service support across the entire drug discovery and development continuum, including many products and services not specific to therapeutic area or indication.

Serving the needs of both small and large molecule developers, we offer a broad range of standard and specialized laboratory services to complement and enhance drug development programs, from discovery through safety and clinical trials. From complete IND-enabling programs to stand-alone assessments, our Safety Assessment team provides a full range of in vivo and in vitro testing services that comply with worldwide regulatory restrictions for the preclinical development of pharmaceuticals.

We provide a comprehensive range of testing programs and equipment to support pharmaceutical development. Our biologics testing solutions and portfolio of microbial quality control systems and services help clients ensure the safety, quality and compliance of their products. We support large molecule manufacturing from early preclinical formulation development through clinical and commercial manufacturing and release.

Exceptional support of the entire drug discovery and development process is a Charles River hallmark. As a customer-focused organization committed to advancing science and helping clients reach their goals, we continually strive to develop solutions that extend our support of their efforts. Because our industry-seasoned professionals have followed the same journey as our clients, we can provide insight into the bigger picture, advice on best practices, skilled staff to extend resources and targeted training to meet the unique challenges they face along the way.